MT-101
Therapeutic angiogenesis, tumor vessel normalization, diabetic retinopathy, AMD, sepsis
PreclinicalActive
Key Facts
Indication
Therapeutic angiogenesis, tumor vessel normalization, diabetic retinopathy, AMD, sepsis
Phase
Preclinical
Status
Active
Company
About MabTics
Innovative antibody platform focused on vessel normalization for oncology, vascular, and eye diseases.
View full company profile